Diffusion-weighted imaging as a non-gadolinium alternative for immediate assessing nonperfused area of adenomyosis after magnetic resonance-guided focused ultrasound (MRgFUS) ablation: a potential technique but with slightly overestimate

article OA: gold CC0 ⤵ 1 in-corpus citation
AI-generated summary by claude@2026-06, 2026-06-08

Diffusion-weighted imaging can assess nonperfused areas after MRgFUS ablation of adenomyosis, though it slightly overestimates the ablated lesion size compared to contrast-enhanced imaging.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by claude@2026-06, 2026-06-09

This single-institution retrospective study evaluated whether diffusion-weighted imaging (DWI) performed on the MRgFUS treatment table within 15 minutes after ablation could measure nonperfused (necrotic) adenomyosis volume without gadolinium, compared with gadolinium-enhanced T1-weighted imaging. Forty-eight Chinese women with symptomatic adenomyosis (focal or diffuse; lesion diameter ≥3.0 cm) underwent MRgFUS, followed by DWI using reduced field-of-view with a single b-value (800 sec/mm²) and contrast-enhanced imaging, with necrotic area defined on CE as the nonenhanced zone; radiologists classified DWI signal patterns and traced lesion boundaries on the maximum slice, with intra-/interobserver consistency assessed by ICC. DWI abnormal signal areas were visually recognizable in all lesions and were essentially corresponding to CE nonperfused areas, but there were notable inconsistencies in DWI signal-type classification (about 12.5% intraobserver and 12.5% interobserver). The paper relates to endometriosis and adenomyosis because it is centrally about adenomyosis after MRgFUS, testing a non-gadolinium DWI alternative for immediate assessment of ablated nonperfused areas.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Background: It is a technical challenge to monitor ablation outcome during magnetic resonance-guided focused ultrasound (MRgFUS) treatment using non-gadolinium technique. The study aimed to investigate the value of diffusion-weighted imaging (DWI) for immediately assessing nonperfused area of adenomyosis after MRgFUS treatment. Methods: We retrospectively included patients with adenomyosis who underwent MRgFUS ablation and underwent both DWI (b=800 sec/mm2) and contrast-enhanced (CE) magnetic resonance (MR) imaging within 15 minutes after treatment. Two blinded observers independently reviewed the DWI scan of the ablated necrotic lesions and measured their area in the central slice of DWI and CE imaging. Consistency and differences in the assessment result were compared. Results: A total of 48 women with adenomyosis (mean age 39.6±4.9 years) were analyzed. Abnormal signals were observed in all 48 adenomyosis lesions on DWI images and could be categorized into 3 types: large area of central low-signal with complete (type 1) or incomplete (type 2) high-signal ring, or inhomogeneous high-signal areas without a ring sign (type 3). Intra- and interobserver intraclass correlation coefficients (ICCs) were 0.84 and 0.80, respectively, for categorizing the DWI signal types (both P<0.001). The DWI abnormal signals and nonperfused areas were essentially corresponding. ICCs were ranged from 0.85 to 0.91 for area measurements using DWI vs. CE MR imaging (all P<0.001). The area of necrotic lesions measured using DWI images was larger than that using CE images (17.17±7.79 vs. 15.41±7.36 cm2, P<0.001). Conclusions: DWI can serve as a non-gadolinium technique for the initial evaluation of nonperfused area of adenomyosis after MRgFUS ablation. However, it is also important to note that DWI may slightly overestimate the nonperfused area.

My notes (saved in your browser only)

Condition tags

adenomyosis

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (1)

Cited by (1)

Source provenance

europepmc
last seen: 2026-06-12T06:13:51.797165+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pmc
last seen: 2026-05-13T20:22:03.195721+00:00
pubmed
last seen: 2026-05-16T00:31:57.365633+00:00
License: CC0 · commercial use OK